
    
      The study is Post-Marketing Surveillance on the Long-Term Use of Spiriva Respimat in Japanese
      patients with mild to moderate persistent asthma. The patient population who receive Spiriva
      Respimat and the safety profile is not expected to change. This study can investigate the
      safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent
      asthma under real-world use
    
  